Review



microarray breast cancer dataset  (Agilent technologies)


Bioz Verified Symbol Agilent technologies is a verified supplier
Bioz Manufacturer Symbol Agilent technologies manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 90

    Structured Review

    Agilent technologies microarray breast cancer dataset
    Microarray Breast Cancer Dataset, supplied by Agilent technologies, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/microarray breast cancer dataset/product/Agilent technologies
    Average 90 stars, based on 1 article reviews
    microarray breast cancer dataset - by Bioz Stars, 2026-06
    90/100 stars

    Images



    Similar Products

    86
    Thermo Fisher public breast cancer affymetrix hgu133a microarray datasets
    Total number of patients, number of patients in each class, and sources of the datasets used in single- and multiomics prediction experiments. <xref ref-type= a " width="250" height="auto" />
    Public Breast Cancer Affymetrix Hgu133a Microarray Datasets, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/public breast cancer affymetrix hgu133a microarray datasets/product/Thermo Fisher
    Average 86 stars, based on 1 article reviews
    public breast cancer affymetrix hgu133a microarray datasets - by Bioz Stars, 2026-06
    86/100 stars
      Buy from Supplier

    90
    Thermo Fisher microarray breast cancer datasets
    Total number of patients, number of patients in each class, and sources of the datasets used in single- and multiomics prediction experiments. <xref ref-type= a " width="250" height="auto" />
    Microarray Breast Cancer Datasets, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/microarray breast cancer datasets/product/Thermo Fisher
    Average 90 stars, based on 1 article reviews
    microarray breast cancer datasets - by Bioz Stars, 2026-06
    90/100 stars
      Buy from Supplier

    90
    Biotechnology Information breast cancer microarray datasets
    Total number of patients, number of patients in each class, and sources of the datasets used in single- and multiomics prediction experiments. <xref ref-type= a " width="250" height="auto" />
    Breast Cancer Microarray Datasets, supplied by Biotechnology Information, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/breast cancer microarray datasets/product/Biotechnology Information
    Average 90 stars, based on 1 article reviews
    breast cancer microarray datasets - by Bioz Stars, 2026-06
    90/100 stars
      Buy from Supplier

    90
    Rosetta Inpharmatics breast cancer microarray datasets
    Total number of patients, number of patients in each class, and sources of the datasets used in single- and multiomics prediction experiments. <xref ref-type= a " width="250" height="auto" />
    Breast Cancer Microarray Datasets, supplied by Rosetta Inpharmatics, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/breast cancer microarray datasets/product/Rosetta Inpharmatics
    Average 90 stars, based on 1 article reviews
    breast cancer microarray datasets - by Bioz Stars, 2026-06
    90/100 stars
      Buy from Supplier

    90
    Agilent technologies microarray breast cancer dataset
    Total number of patients, number of patients in each class, and sources of the datasets used in single- and multiomics prediction experiments. <xref ref-type= a " width="250" height="auto" />
    Microarray Breast Cancer Dataset, supplied by Agilent technologies, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/microarray breast cancer dataset/product/Agilent technologies
    Average 90 stars, based on 1 article reviews
    microarray breast cancer dataset - by Bioz Stars, 2026-06
    90/100 stars
      Buy from Supplier

    90
    Broad Institute Inc breast cancer microarray dataset
    Total number of patients, number of patients in each class, and sources of the datasets used in single- and multiomics prediction experiments. <xref ref-type= a " width="250" height="auto" />
    Breast Cancer Microarray Dataset, supplied by Broad Institute Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/breast cancer microarray dataset/product/Broad Institute Inc
    Average 90 stars, based on 1 article reviews
    breast cancer microarray dataset - by Bioz Stars, 2026-06
    90/100 stars
      Buy from Supplier

    86
    Thermo Fisher breast cancer affymetrix hg u133a microarray dataset
    Total number of patients, number of patients in each class, and sources of the datasets used in single- and multiomics prediction experiments. <xref ref-type= a " width="250" height="auto" />
    Breast Cancer Affymetrix Hg U133a Microarray Dataset, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/breast cancer affymetrix hg u133a microarray dataset/product/Thermo Fisher
    Average 86 stars, based on 1 article reviews
    breast cancer affymetrix hg u133a microarray dataset - by Bioz Stars, 2026-06
    86/100 stars
      Buy from Supplier

    Image Search Results


    Total number of patients, number of patients in each class, and sources of the datasets used in single- and multiomics prediction experiments. <xref ref-type= a " width="100%" height="100%">

    Journal: Bioinformatics

    Article Title: COmic: convolutional kernel networks for interpretable end-to-end learning on (multi-)omics data

    doi: 10.1093/bioinformatics/btad204

    Figure Lengend Snippet: Total number of patients, number of patients in each class, and sources of the datasets used in single- and multiomics prediction experiments. a

    Article Snippet: We trained COmic models on six different public breast cancer Affymetrix HGU133A microarray datasets (GSE11121, GSE1456, GSE2034, GSE2990, GSE4922, and GSE7390) that were previously used to benchmark knowledge-based classification methods that use interaction network priors.

    Techniques:

    (A ) Cross-validation performance of COmic models compared to previously published methods. The boxplots show the 10 mean auROC validation scores of a 10-times repeated 10-fold cross-validation over each of the 6 breast cancer cohorts. Performance of COmic models is shown in orange (last two boxes on the right side). The center line of each box indicates the median. The height of the boxes represents the interquartile range (IQR) with the upper and lower whiskers set to 1.5 times the IQR. Outliers are depicted by black diamonds. Notches represent the confidence interval (CI) around the median and were calculated using bootstrapping with 10 000 iterations. (B) Visualizing the global interpretation capabilities of a pooling-based COmic model. Each box represents one of the 50 pathways and was created using the pathway weights of the models trained on the six publicly available breast cancer cohorts: GSE11121, GSE1456, GSE2034, GSE2990, GSE4922, and GSE7390. The boxplots are defined as in (A) but without notches (CIs not shown). (C) Visualizing the local interpretation capabilities of an attention-based COmic model. Each heat-map shows the attention weights for each of the 50 pathways for three different patients. The model was trained on the GSE11121 cohort. Patient 1 was correctly classified to have a metastasis-free survival (DMFS) above 5 years. Patient 2 was correctly classified to have a DMFS below 5 years. Patient 3 was wrongly classified to have a DMFS above 5 years, while the DMFS of Patient 3 was actually below 5 years. More examples can be found in the supplement. (D) Mean training time of pooling-based and attention-based COmic models for differently sized datasets. The number of samples is 100, 1000, 10 000, and 100 000, respectively. Training was repeated five times per dataset and the stars represent the mean training time. The blue and green lines show the results for a fixed batch size of 32 samples per batch. The red and yellow lines show the results for an adaptive batch size of 1% of the dataset size (i.e. the batch size was 1 for the dataset with 100 samples and 1000 for the dataset with 100 000 samples). Each model was trained for 200 epochs.

    Journal: Bioinformatics

    Article Title: COmic: convolutional kernel networks for interpretable end-to-end learning on (multi-)omics data

    doi: 10.1093/bioinformatics/btad204

    Figure Lengend Snippet: (A ) Cross-validation performance of COmic models compared to previously published methods. The boxplots show the 10 mean auROC validation scores of a 10-times repeated 10-fold cross-validation over each of the 6 breast cancer cohorts. Performance of COmic models is shown in orange (last two boxes on the right side). The center line of each box indicates the median. The height of the boxes represents the interquartile range (IQR) with the upper and lower whiskers set to 1.5 times the IQR. Outliers are depicted by black diamonds. Notches represent the confidence interval (CI) around the median and were calculated using bootstrapping with 10 000 iterations. (B) Visualizing the global interpretation capabilities of a pooling-based COmic model. Each box represents one of the 50 pathways and was created using the pathway weights of the models trained on the six publicly available breast cancer cohorts: GSE11121, GSE1456, GSE2034, GSE2990, GSE4922, and GSE7390. The boxplots are defined as in (A) but without notches (CIs not shown). (C) Visualizing the local interpretation capabilities of an attention-based COmic model. Each heat-map shows the attention weights for each of the 50 pathways for three different patients. The model was trained on the GSE11121 cohort. Patient 1 was correctly classified to have a metastasis-free survival (DMFS) above 5 years. Patient 2 was correctly classified to have a DMFS below 5 years. Patient 3 was wrongly classified to have a DMFS above 5 years, while the DMFS of Patient 3 was actually below 5 years. More examples can be found in the supplement. (D) Mean training time of pooling-based and attention-based COmic models for differently sized datasets. The number of samples is 100, 1000, 10 000, and 100 000, respectively. Training was repeated five times per dataset and the stars represent the mean training time. The blue and green lines show the results for a fixed batch size of 32 samples per batch. The red and yellow lines show the results for an adaptive batch size of 1% of the dataset size (i.e. the batch size was 1 for the dataset with 100 samples and 1000 for the dataset with 100 000 samples). Each model was trained for 200 epochs.

    Article Snippet: We trained COmic models on six different public breast cancer Affymetrix HGU133A microarray datasets (GSE11121, GSE1456, GSE2034, GSE2990, GSE4922, and GSE7390) that were previously used to benchmark knowledge-based classification methods that use interaction network priors.

    Techniques: